Sweden’s Gesynta ‘Phase IIa Ready’ After Private Placing

Lead Asset Aims To Treat Chronic Inflammation In Systemic Sclerosis

 
• By Sten Stovall
  
Stacked_Krona_Banknotes
Investors in SEK190m placement included Swedish government’s Industrifonden • Source: Shutterstock

More from Clinical Trials

More from R&D